Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Expert Review of Hematology

Volumn 3, Issue 6, 2010, Pages 665-673

  Giles, Francis J ^a   Rosti, Gianantonio ^b   Beris, Photis ^c   Clark, Richard E ^d   Le Coutre, Philipp ^e   Mahon, Francois Xavier ^f   Steegmann, Juan Luis ^g   Valent, Peter ^h   Saglio, Giuseppe ⁱ  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

ABL kinase inhibitors; chronic myeloid leukemia; ENESTnd; FDA approval; first line therapy; imatinib; nilotinib

Indexed keywords

ANAGRELIDE; DASATINIB; HYDROXYUREA; IMATINIB; KETOCONAZOLE; MIDAZOLAM; NILOTINIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG POTENCY; DRUG TREATMENT FAILURE; EYELID EDEMA; FATIGUE; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; MUSCLE SPASM; MYALGIA; NAUSEA; NONHUMAN; PATIENT MONITORING; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78649501550     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.61     Document Type: Review

References (21)

1. Goldman JM. Chronic myeloid leukemia: Reversing the chronic phase. J. Clin. Oncol. 28, 363-365 (2010).
2. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
3. Kelly K, Swords R, Mahalingam D, Giles F. Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents. Leuk. Lymphoma 51(8), 1399-1413 (2010).
4. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006). (Pubitemid 43882350)
5. Singer JB, Shou Y, Giles F et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21, 2311-2315 (2007).
6. Swords R, Mahalingam D, Padmanabhan S et al. Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des. Devel. Ther. 3, 89-101 (2009).
7. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23, 1698-1707 (2009).
8. Swords R, Alvarado Y, Cortes J, Giles FG. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr. Hematol. Malig. Rep. 2, 83-88 (2007). (Pubitemid 46732564)
9. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041-6051 (2009).
10. Giles F, Kantarjian H, le Coutre P et al. Nilotinib induces rapid and durable responses with 24-month minimum follow-up in patients with imatinibresistant or intolerant chronic myeloid leukaemia in blast crisis (CML-BC). Haematologica 92(Suppl. 2), Abstract No. 1138 (2010).
11. Giles FJ, Abruzzese E, Rosti G et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24(7), 1299-1301 (2010).
12. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008).
13. Cortes JE, Jones D, O'Brien S et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 28, 398-404 (2010).
14. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270 (2010).
15. Rosti G, Palandri F, Castagnetti F et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114, 4933-4938 (2009).
16. Cortes JE, Jones D, O'Brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 28, 392-397 (2010).
17. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251-2259 (2010).
18. Hochhaus A, Lobo C, Pasquini R et al. Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): ENESTnd beyond 1 year. Presented at: 15th Congress of the European Haematology Association. Barcelona, Spain, 10-13 June 2010 (Abstract 1113).
19. Larson RA, le Coutre PD, Reiffers J et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. J. Clin. Oncol. 28(Suppl. 15), 6501 (2010).
20. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 4, 99-105 (2009).
21. Mahon FX, Réa D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. DOI:10.1016/S1470- 2045(10)70233-3 (2010) (Epub ahead of print).